Lin Zhou[Author] - Search Results

Year	Number of Results
2002	12
2003	10
2004	12
2005	12
2006	16
2007	23
2008	42
2009	60
2010	67
2011	88
2012	81
2013	118
2014	141
2015	150
2016	178
2017	163
2018	184
2019	189
2020	241
2021	241
2022	267
2023	247
2024	99

1

CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis.

Jiang Y, Zhao J, Li R, Liu Y, Zhou L, Wang C, Lv C, Gao L, Cui D. Jiang Y, et al. Among authors: zhou l. J Exp Clin Cancer Res. 2022 Oct 20;41(1):307. doi: 10.1186/s13046-022-02518-8. J Exp Clin Cancer Res. 2022. PMID: 36266731 Free PMC article.

2

The etiology of poststroke-depression: a hypothesis involving HPA axis.

Zhou L, Wang T, Yu Y, Li M, Sun X, Song W, Wang Y, Zhang C, Fu F. Zhou L, et al. Biomed Pharmacother. 2022 Jul;151:113146. doi: 10.1016/j.biopha.2022.113146. Epub 2022 May 26. Biomed Pharmacother. 2022. PMID: 35643064 Free article. Review.

3

Clinical features of NOTCH2NLC-related neuronal intranuclear inclusion disease.

Tian Y, Zhou L, Gao J, Jiao B, Zhang S, Xiao Q, Xue J, Wang Y, Liang H, Liu Y, Ji G, Mao C, Liu C, Dong L, Zhang L, Zhang S, Yi J, Zhao G, Luo Y, Sun Q, Zhou Y, Yi F, Chen X, Zhou C, Xie N, Luo M, Yao L, Hu Y, Zhang M, Zeng Q, Fang L, Long HY, Xie Y, Weng L, Chen S, Du J, Xu Q, Feng L, Huang Q, Hou X, Wang J, Xie B, Zhou L, Long L, Guo JF, Wang J, Yan X, Jiang H, Xu H, Duan R, Tang B, Shen L. Tian Y, et al. Among authors: zhou l. J Neurol Neurosurg Psychiatry. 2022 Dec;93(12):1289-1298. doi: 10.1136/jnnp-2022-329772. Epub 2022 Sep 23. J Neurol Neurosurg Psychiatry. 2022. PMID: 36150844 Free PMC article.

4

Targeting SOST using a small-molecule compound retards breast cancer bone metastasis.

Sun L, Zhang Y, Chen G, Ji Y, Ma Q, Qiao X, Wu S, Zhou L, Bu J, Zhu X, Zhang X, Jiang X, Liu C, Li X, Liu Y, Yang Y, Liu C. Sun L, et al. Among authors: zhou l. Mol Cancer. 2022 Dec 29;21(1):228. doi: 10.1186/s12943-022-01697-4. Mol Cancer. 2022. PMID: 36581888 Free PMC article.

5

Downregulation of G protein-coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury.

Yang D, Tang M, Zhang M, Ren H, Li X, Zhang Z, He B, Peng S, Wang W, Fang D, Song Y, Xiong Y, Liu ZZ, Liang L, Shi W, Fu C, Hu Y, Jose PA, Zhou L, Han Y, Zeng C. Yang D, et al. Among authors: zhou l. Kidney Int. 2023 Apr;103(4):719-734. doi: 10.1016/j.kint.2022.12.023. Epub 2023 Jan 18. Kidney Int. 2023. PMID: 36669643

6

Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection.

Wang P, Song Q, Ren J, Zhang W, Wang Y, Zhou L, Wang D, Chen K, Jiang L, Zhang B, Chen W, Qu C, Zhao H, Jiao Y. Wang P, et al. Among authors: zhou l. Sci Transl Med. 2022 Nov 23;14(672):eabp8704. doi: 10.1126/scitranslmed.abp8704. Epub 2022 Nov 23. Sci Transl Med. 2022. PMID: 36417488

7

The association between the body roundness index and the risk of colorectal cancer: a cross-sectional study.

Gao W, Jin L, Li D, Zhang Y, Zhao W, Zhao Y, Gao J, Zhou L, Chen P, Dong G. Gao W, et al. Among authors: zhou l. Lipids Health Dis. 2023 Apr 18;22(1):53. doi: 10.1186/s12944-023-01814-2. Lipids Health Dis. 2023. PMID: 37072848 Free PMC article.

8

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.

Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H. Yang X, et al. Among authors: zhou l. Hepatol Int. 2023 Jun;17(3):709-719. doi: 10.1007/s12072-022-10480-y. Epub 2023 Feb 8. Hepatol Int. 2023. PMID: 36753026 Free PMC article.

9

Liver organoid culture methods.

Hu Y, Hu X, Luo J, Huang J, Sun Y, Li H, Qiao Y, Wu H, Li J, Zhou L, Zheng S. Hu Y, et al. Among authors: zhou l. Cell Biosci. 2023 Nov 1;13(1):197. doi: 10.1186/s13578-023-01136-x. Cell Biosci. 2023. PMID: 37915043 Free PMC article. Review.

10

Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.

Wu Q, Pan C, Zhou Y, Wang S, Xie L, Zhou W, Ding L, Chen T, Qian J, Su R, Gao X, Mei Z, Qiao Y, Yin S, Wu Y, Wang J, Zhou L, Zheng S. Wu Q, et al. Among authors: zhou l. Hepatology. 2023 Nov 1;78(5):1402-1417. doi: 10.1097/HEP.0000000000000320. Epub 2023 Feb 23. Hepatology. 2023. PMID: 36811396

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

2,342 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

2,342 results

Results by year